Research ArticleArticle
Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results
Roy M. Fleischmann, Anne-Marie Halland, Marek Brzosko, Ruben Burgos-Vargas, Christopher Mela, Emma Vernon and Joel M. Kremer
The Journal of Rheumatology January 2013, jrheum.120447; DOI: https://doi.org/10.3899/jrheum.120447
Roy M. Fleischmann
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Anne-Marie Halland
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Marek Brzosko
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Ruben Burgos-Vargas
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Christopher Mela
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Emma Vernon
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Joel M. Kremer
From the Metroplex Clinic Research Center, Dallas, Texas, USA; Panorama Medical Center, Cape Town, South Africa; Rheumatology and Internal Diseases Clinic, Pomeranian Medical University, Szczecin, Poland; Hospital General de México, Universidad Nacional Autónoma de México, Mexico City, Mexico; Roche Products Ltd., Welwyn Garden City, UK; and Albany Medical College and The Center for Rheumatology, Albany, New York, USA. Supported by F. Hoffmann-La Roche Ltd. R.M. Fleischmann has received research grants and consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Janssen, UCB, BMS, Roche, Genentech, Lexicon, Sanofi-Aventis, Lilly, MSD, Pfizer, and Regeneron. A. Halland has received honoraria from Roche and Abbott (less than $10,000). M. Brzosko has received lecture/instructor fees from Roche, Abbott, Amgen, Pfizer, MSD, Novartis, Schering-Plough, and Sanofi-Aventis. R. Burgos-Vargas has received research grants from Roche and consulting fees and speakers fees from Abbott, BMS, MSD, Roche, and UCB. J.M. Kremer has received research grants from Abbott, BMS, Genentech, Janssen, Pfizer, and UCB and is on the speakers bureau for Abbott, BMS, and Genentech R.M. Fleischmann, MD, Clinical Professor of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, Metroplex Clinic Research Center; A-M. Halland, MBChB, FCP, MMed, Panorama Medical Center; M. Brzosko, MD, PhD, Rheumatology and Internal Diseases Clinic, Pomeranian Medical University; R. Burgos-Vargas, MD, Hospital General de México, Universidad Nacional Autónoma de México; C. Mela, PhD; E. Vernon, MSc, Roche Products Ltd.; J.M. Kremer, MD, Albany Medical College and The Center for Rheumatology. Address correspondence to Dr. R. Fleischmann, Metroplex Clinical Research Center (MCRC), 8144 Walnut Hill Lane, Dallas, TX 75231, USA. E-mail: RFleischmann@arthdocs.com Accepted for publication October 19, 2012.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results
Roy M. Fleischmann, Anne-Marie Halland, Marek Brzosko, Ruben Burgos-Vargas, Christopher Mela, Emma Vernon, Joel M. Kremer
The Journal of Rheumatology Jan 2013, jrheum.120447; DOI: 10.3899/jrheum.120447
Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study 2-year Results
Roy M. Fleischmann, Anne-Marie Halland, Marek Brzosko, Ruben Burgos-Vargas, Christopher Mela, Emma Vernon, Joel M. Kremer
The Journal of Rheumatology Jan 2013, jrheum.120447; DOI: 10.3899/jrheum.120447